PMC0
10.1038%2Fsj.bjc.6601786
discussion
Combinations of infusional 5-FU/FA with MMC are commonly used in gastrointestinal cancer (Hartmann et al, >>2003<<). In gastric cancer, MMC (10 mg m−2) added every third week to weekly infusional 5-FU/FA yielded a response rate of 54%, and a median overall survival of 10.2 months (Hofheinz et al, 2002).
In gastric cancer, MMC (10 mg m−2) added every third week to weekly infusional 5-FU/FA yielded a response rate of 54%, and a median overall survival of 10.2 months (Hofheinz et al, >>2002<<). Ross et al (2002) reported the results of a randomised study comparing ECF (3-weekly epirubicin and cisplatin in combination with protracted venous infusional (PVI) 5-FU 200 mg m−2 daily) to MCF (MMC 7 mg m−2 every 6 weeks and 3-weekly
In gastric cancer, MMC (10 mg m−2) added every third week to weekly infusional 5-FU/FA yielded a response rate of 54%, and a median overall survival of 10.2 months (Hofheinz et al, 2002). Ross et al (>>2002<<) reported the results of a randomised study comparing ECF (3-weekly epirubicin and cisplatin in combination with protracted venous infusional (PVI) 5-FU 200 mg m−2 daily) to MCF (MMC 7 mg m−2 every 6 weeks and 3-weekly cisplatin with
For patients with metastatic colorectal cancer, several studies on combination therapy of MMC and infusional 5-FU in first- or second-line protocols have been published (e.g. Ross et al, >>1997<<; Chester et al, 2000; Grumett et al, 2001). Administered as salvage treatment, the addition of MMC to 5-FU-containing regimens may overcome resistance to 5-FU.
For patients with metastatic colorectal cancer, several studies on combination therapy of MMC and infusional 5-FU in first- or second-line protocols have been published (e.g. Ross et al, 1997; Chester et al, 2000; Grumett et al, >>2001<<). Administered as salvage treatment, the addition of MMC to 5-FU-containing regimens may overcome resistance to 5-FU.
In both, colorectal and pancreatic cancer, protracted infusional 5-FU plus MMC resulted in a superior response rate in comparison with 5-FU alone, but this did not translate into a survival advantage (Ross et al, >>1997<<; Maisey et al, 2002).
In both, colorectal and pancreatic cancer, protracted infusional 5-FU plus MMC resulted in a superior response rate in comparison with 5-FU alone, but this did not translate into a survival advantage (Ross et al, 1997; Maisey et al, >>2002<<).
Anthracyclines are used in combination regimens in gastric cancer (e.g. Ross et al, >>2002<<) or pancreatic cancer (e.g. Neri et al, 2002). They formed part of the FAM (5-FU, doxorubicin, MMC) and FAMtx (5-FU, doxorubicin, methotrexate) regimens, respectively.
Anthracyclines are used in combination regimens in gastric cancer (e.g. Ross et al, 2002) or pancreatic cancer (e.g. Neri et al, >>2002<<). They formed part of the FAM (5-FU, doxorubicin, MMC) and FAMtx (5-FU, doxorubicin, methotrexate) regimens, respectively.
The FAM has been shown to be superior to best supportive care in pancreatic carcinoma (Palmer et al, >>1994<<), although trials have failed to clearly demonstrate an advantage over single agent 5-FU (Cullinan et al, 1985).
The FAM has been shown to be superior to best supportive care in pancreatic carcinoma (Palmer et al, 1994), although trials have failed to clearly demonstrate an advantage over single agent 5-FU (Cullinan et al, >>1985<<).
5-Fluorouracil and MMC were planned for use at 75% of the doses administered in our former studies (Hofheinz et al, >>2002<<; Hartmann et al, 2003) and the Caelyx dose was escalated.
5-Fluorouracil and MMC were planned for use at 75% of the doses administered in our former studies (Hofheinz et al, 2002; Hartmann et al, >>2003<<) and the Caelyx dose was escalated.